Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
148 Cards in this Set
- Front
- Back
activities of the renin-angiotensin system
|
bp regulation
secretio of aldosterone renal blood flow Na excretion cns effects: enhance sns ans tissue-angiotensin system |
|
angiotensin work on these receptors
|
AT 1-4
|
|
ang 3 and 4 work on the --- receptors
|
AT4
|
|
ang 1-7 work on the --- receptors
|
Mas-R
|
|
Mas-R actions
|
vasodilation
natriuresis |
|
at1 receptor actions
|
vasoconstriction
aldosteroe Na retention Cell proliferation |
|
at2 actions
|
vasodilation
aniproliferative apoptosis (almost opposite to at1. . . prominent role in fetal development) |
|
renin is a --- enzyme
|
protease
|
|
renin cleaves -- aa off antioteninogen to form inactive ---- --
|
4
angiotensin 1 |
|
what is renin synthesized as
|
pre-prohormone
|
|
renin is synthesized as pre-prohormone and processed to ------ which is inacitve
|
pro-renin
|
|
what synthesizes, stores and releases renin
|
juxtaglomerular cells in the afferent arterioles
|
|
t/f
juxtaglomerular cells in the efferent arterioles synthesizes, stores, and release renin |
afferent
|
|
what controls the RAS system
|
rate of release of kidneys
|
|
secretion of renin controlled by
|
renal baroreceptors
changes in NaCl in macula densa SNS |
|
secretion of the renin controlled by renal -----, changes in --- in macula densa, and the sns system
|
baroreceptors
NaCl |
|
renal baroreceptors responds to ------ of afferent arterioles
for example decreased perfusion, will lead to an increae in --- release |
stretch
renin |
|
macula densa responds to changes in Cl in the -- ----
|
distal tubule
|
|
--- Cl will stimulate renin release
|
decrease
|
|
what innervates juxtaglomerular cells
|
SNS
|
|
renal ---- --- controls release of renin
|
nerve activity
|
|
--- activation increases renin release
|
sympathetic
|
|
---receptors increase renin release
|
beta 1
|
|
--- receptors decrease renin release
|
alpha 1
|
|
which has a bigger role beta 1 or alpha 1
|
beta 1
|
|
ang 2 vasoconstricts thru which receptor
|
AT2
|
|
ang2 stimulates --- secretion
|
aldosterone
|
|
thru which receptors will ang 2 cause aldosterone secretion, renal vasoconstriciton, and increase sympathetic outflow by central action
|
AT1
|
|
what will inhibits renin release via neg feedback
|
ang 2
|
|
ang 2 increase ---- outflow by central action
|
sympathetic
|
|
ang 2 increase -- release by acting on the ---- receptors
|
NE
presynaptic |
|
via what receptors does ang 2 increase ne
|
AT1
|
|
ang 2 stimulate ---, --, and ----- centrally
|
thirst
Na appetite ADH secretion |
|
what also regulates thirst
|
cns
|
|
ang 2 causes cell/tissue ---- and cardiac ----- after mi via what recetpors
|
hypertrophy
remodeling AT1 |
|
t 1/2 of ang 2
|
short
15-60 sec |
|
--- removes amino terminal aspartate to form ANG 3
|
aminopeptidase
|
|
t/f
ang 3 has limited activity |
t
|
|
what cleaves ang 3 to inactive products
|
angiotensinase
|
|
ang 2 actions on bp
how |
10-25% effective on BP
increase aldosterone via AT1 and AT4 |
|
ang 3 (3-8) increase aldosterone via -- and --- receptors
|
AT1
AT 4 |
|
ang 4 (3-8) works on --- and ----
it counteracts ang ---- |
memory
learning ang 2 |
|
angiotensin (1-7) has opposite effects on ang ---
|
ang 2
|
|
overactive RAS can lead to:
|
HTN
CHF Diabetic nephropathy myocardial remodeling post MI |
|
ace: dipeptdyl carboxypeptidase removes -- aa fromteh carboxy termnal of -----
|
2
peptide |
|
t/f
ace selective for ang 1 |
f
not selective |
|
ace inactivates -----, cleaves ---- and ----
|
inactivates bradykinin
cleaves enkephalins cleaves sub P |
|
where is ace found
esp? |
vascular endothelial cell
esp lungs |
|
why doesn't ace cleave ang 2
|
due to proline
2nd to last aa |
|
ace is enzyme w/ -- binding domain
|
Zn
|
|
acei have a functional group that binds the --- at the active site of the enzyme
|
An
|
|
what the main difference in acei
|
functional group that binds the Zn moiety
|
|
which acei has a sulfhydryl group
|
captropril
|
|
which acei has a phosphyinly group
|
fosinopril
|
|
which acei has a carboxyl group
|
all other inhibitors
|
|
when acei bind to zinc what does this prevent
|
ang 1 from bind and creating ang 2
|
|
acei inhibit ---- vasoconstriction
|
ang 2
|
|
ace i inhibit --- vasoconstriction
|
ang 2
renal |
|
acei prevents synthesis of ---- and ---- reabsorption
|
aldosterone
Na |
|
acei inhibit --- metabolism
|
bradykinin
so more bradykinin to vasodilate |
|
acei inhibit ang 2 mediated incease in -- release
|
NE
both centrally and peripherally |
|
due to acei there will be a neg feedback to increase --- and ----
|
ang 1
renin |
|
how are acei different, same
|
different: t 1/2 and metabolism
same: MOA and effects |
|
prodrug esters of acei have to be activated in the --- to be active
|
liver
|
|
which acei don't have to be activated
|
captopril
lisinopril |
|
active form eliminated thru
|
kidneys
|
|
which active form not eliminated thru kidneys
|
fosinopril
|
|
why is captopril no a q day med
|
short t 1/2
|
|
how is fosinopril eliminated
|
balanced elimination btw liver and kidneys
|
|
dosage form of enalaprilat
|
iv
|
|
why migh acei need bid dosing
|
towards end of dosing interval may loose effectiveness
|
|
w/ acei there's a --- dose response at low doses
higher doses --- dose response |
steep
flatter if you double dose does not mean you'll double the effect |
|
how do acei tx htn
|
decrease tpr: sbp and dbp
decrease L ventricular hypertrophy due to elevated bp |
|
who will be less effected by acei
less effective as MONOTHERAPY |
blacks
due to low renin, vol senisitive htn |
|
when used w/ ---- acei are equally effective in blacks and whites
|
diureticq
|
|
acei are the preferred antihtn in ----
|
diabetics
|
|
who should receive acei unless contraindicated
|
LV dysfunction
|
|
How do acei help w/ l ventricle dysfunction. . .chf
decrease -- remodeling and hypertrophy decrease vascular ---- (afterload) decrease ----, increase ------ |
LV
resistance preload increase CO |
|
acei will delay or prevent the progression of -----
decrease the incidence of --- or hospitalization |
CHF
MI |
|
why use acei post mi
|
decrease myocaridal remodeling following infarction
decrease overall mortality when given post mi |
|
whic dm pt gets acei
|
thos wil at least 1 risk for cv disease
|
|
acei given to pts at high risk for --- ---
|
cv events
|
|
acei given to pts w/ establised ------
|
CAD
|
|
diabetic nephropathy decrease ----- pressure and --- of w/in kidney
|
glomerular
remodeling |
|
acei --- and ---- progression of renal disease in dm
|
prevent
delay |
|
diabetic nephropathy slow progression of renal disease in other -----
|
nephropatites
|
|
dry cough w/ acei due to
|
bradykinin and sub p accumulation in the lungs
|
|
when do u see dry cough in acei
|
from week 1 to 6 mo
|
|
t/f
dry cough r/t to dose and specific agent |
f
not related |
|
dry cough mostly seen in men/women
|
women
|
|
t/f
always d/c acei if pt has a cough |
f
if bothersome |
|
hypo/hyper-kalemia seen w/ acei
|
hyperkalemia
mainly seen w/ renal disease or w k sparing diuretics, supplements/salts |
|
when will the pt have hypotension w/ acei
|
first dose
upwards titration due to sudden wipe out of angiotensin |
|
when is hypotension most common
|
in Na depletion
CHF multi antiHTN meds |
|
why might acei cause renal fx impairment
|
cuz renal bl flow might be dependent on ANG 2
acei will decrease ang 2 and decrease GFR |
|
how do you use acei w/ renal failure
|
use cautiously, low doses move upward slowly
|
|
acei should not be used w/ ---- and -----
|
aortic stenosis
renal artery stenosis |
|
why shouldn't acei be uses w/ aortic stenosis and renal artery stenosis
|
cuz bl flow around plaque might be dependent on the angiotensin
so it's removed. . .ischemia |
|
angioedema is rapid swelling of
|
nose, throat, mouth, larynx, lips, and tongue
|
|
when does angioedema develop
|
w/in first week
|
|
t/f
angioedema irreversible |
f
reversible if drug removed |
|
what might cause angioedema
|
bradykinin accumulation
|
|
when is acei ci in pregnancy
|
2nd and 3rd trimesters
birth defects and fetal death |
|
which receptors are common in the fetus
|
AT2
|
|
pruritic skin rash most often w/ ---
|
captopril
|
|
--- disturbances is a se
|
taste
binding of zinc drugs |
|
--- can decrease ace inhibitors effects
|
NSAIDS
|
|
how can nsaids decrease acei effects
|
blocks bradykinin mediated relaxation due to PGs
|
|
limiting factor of acei
|
there are other pathways for ang 2 production:
trypsin cathepsin chymase |
|
to help w/ limiting factor of acei what do you do
|
block the receptor
|
|
which receptor expressed widely
|
AT1
heart endothelium vsm kidney |
|
at2 expressed during ----
|
development
limited in adults |
|
why a sustained blockade at AT1 receptors
|
high affinity binding
slow dissociation |
|
actions of AT1 receptor blockade
|
vasodilation
renal vasodilation decrease aldosterone decrease Na reabsorption decrease NE (presynaptic) decrease preload/afterload/vascular resistance |
|
which is better at reducing effects of ang 2 at AT1 receptor
|
ARB's
|
|
arb's indirectly activate ---- receptors by directly increasing -----
|
AT2
ang2 (at2 vasodilates) |
|
disadvantae of arb
|
don't inhibit breakdown of bradykinin
so bradykinin is broken down; this helped w/ vasodilation |
|
how are acei eliminated
arb's? |
acei: renal
arb: renal and bile |
|
15% of this arb is converted to 5-carboxycylic acid metabolite
|
losartan
|
|
at1 ---- at starting doses for most arb's
dose response ----- |
saturated
nonlinear so if you increase dose don't see much incease in effects |
|
why AT1 receptors saturated at starting doses
|
cuz of high affinity
|
|
which arb is the only fda approved med for HG
|
valsartan
used when can't tolerate acei |
|
which is preferred for diabetic nephropathy
|
arb's for renoprotection in type 2
|
|
t/f
arb preffered for diabetic nephropathy for type 1 dm |
f
type 2 |
|
for dm nephropaty which is give acei or arb for type 1
|
acei
|
|
initial use of arb worsens hf, but
|
long term beneficial
|
|
t/f
arb recommended for first line tx for simple MI |
f
not first line |
|
valsartan as effective as ----- in mi pts w/ --- ---- ---
|
captopril
left ventricular dysfunction |
|
when do yu use arb in post mi
|
when can't tolerate acei
|
|
se of arb
----kalemia |
hyperkalemia
esp w/ renal disease or k sparing diuretics |
|
hypotension w/ --- ---- effect w/ arbs
|
first dose
|
|
why might there be impairment of renal fx w/ arb
|
ang 2 important for renal fx
|
|
when are arb ci in pregnancy
|
2-3 trimester
|
|
dosing for hf
|
start low and titrate up
|
|
arbs should not be used for
|
aortic stenosis
renal artery stenosis |
|
t/f
arbs cause cough |
f
|
|
direct renin inhibitor
|
aliskiren
|
|
aliskiren is --- active
dosing |
orally acitve
once daily |
|
what will decrease absorption by 71% of aliskiren
|
high fat
|
|
aliskiren has -- bioavailabilty
|
low
|
|
will aliskiren effect bradykinin levels
|
no
|
|
aliskiren mainly excreted ----- in the feces
|
unchanged
|
|
arbs used in combo w/ --- are more beneficial
|
diuretics
|
|
arbs --- effective in salt-sensitive form of htn
|
less
so use diuretic |
|
which is better: aliskiren monotherapy or in combo
|
in combo w/ hctz and valsartan
|
|
se of aliskiren
|
ha
dizziness gi: diarrhea, dyspepsia rash angioedema: although less than acei hyperkalemia: when in combe w/ valsartan, so monitor electrolytes |
|
over time there might be an increase in --- w/ renin inhibitors
|
renin
|
|
renin inhibitors have a --- dose response curve
|
shallow
so double dose does not double the effect renin inhibitors might lose effectiveness |